Merck: halts experimental hepatitis C treatments.
(CercleFinance.com) - Merck has announced that it has decided to discontinue the development of its combined experimental regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C.
This strategic decision has been made on the basis of available Phase II efficacy data and in consideration of the increasing number of treatment options available to patients with this disease.
We will continue to study Zepatier (elbasvir and grazoprevir) to understand even more about its role in the treatment of the hepatitis C infection, said Eliav Barr, at Merck Research Laboratories.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This strategic decision has been made on the basis of available Phase II efficacy data and in consideration of the increasing number of treatment options available to patients with this disease.
We will continue to study Zepatier (elbasvir and grazoprevir) to understand even more about its role in the treatment of the hepatitis C infection, said Eliav Barr, at Merck Research Laboratories.
Copyright (c) 2017 CercleFinance.com. All rights reserved.